Huntington,s disease and Huntington,s disease-like syndromes: An overview

Current Opinion in Neurology

Volumn 26, Issue 4, 2013, Pages 420-427

  Gövert, Felix ^a   Schneider, Susanne A ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

chorea; differential diagnosis; Huntington's disease; Huntington's disease like disorders; spinocerebellar ataxia type 17

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; LEVODOPA; PREDNISONE; TETRABENAZINE;

AUTOSOMAL DOMINANT DISORDER; BENIGN HEREDITARY CHOREA; CHOREA-ACANTHOCYTOSIS; CLINICAL FEATURE; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; HUMAN; HUNTINGTON CHOREA; HUNTINGTON DISEASE LIKE 1; HUNTINGTON DISEASE LIKE 2; HUNTINGTON DISEASE LIKE 3; HUNTINGTON DISEASE LIKE 4; HUNTINGTON DISEASE LIKE SYNDROME; JAPANESE; MCLEOD SYNDROME; NEUROFERRITINOPATHY; PHENOTYPE; RARE DISEASE; REVIEW; WILSON DISEASE;

GENETIC PREDISPOSITION TO DISEASE; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; HUNTINGTON DISEASE; IRON METABOLISM DISORDERS; MEMBRANE PROTEINS; MUTATION; MYOCLONIC EPILEPSIES, PROGRESSIVE; NEUROAXONAL DYSTROPHIES; PHENOTYPE; PRIONS; SYNDROME; TATA-BOX BINDING PROTEIN;

EID: 84880742022     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283632d90     Document Type: Review

References (83)

1. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011; 10:31-42.
2. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012; 11:42-53.
3. Wild EJ, Tabrizi SJ. Predict-HD and the future of therapeutic trials. Lancet Neurol 2006; 5:724-725. (Pubitemid 44209398)
4. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10:83-98.
5. Wild EJ, Tabrizi SJ. Huntington's disease phenocopy syndromes. Curr Opin Neurol 2007; 20:681-687. (Pubitemid 350085010)
6. Moore RC, Xiang F, Monaghan J, et al. Huntington disease phenocopy is a familial prion disease. Am J Hum Genet 2001; 69:1385-1388. (Pubitemid 33124219)
7. Schneider SA, Bhatia KP. Huntington's disease look-alikes. Handb Clin Neurol 2011; 100:101-112.
8. Martino D, Stamelou M, Bhatia KP. The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician. J Neurol Neurosurg Psychiatry 2012; 84:650-656.
9. Xiang F, Almqvist EW, Huq M, et al. A Huntington disease-like neurodegenerative disorder maps to chromosome 20p. Am J Hum Genet 1998; 63:1431-1438. (Pubitemid 30418541)
10. Laplanche JL, Hachimi KH, Durieux I, et al. Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. Brain 1999; 122 (Pt 12):2375-2386.
11. Holmes SE, O'Hearn E, Rosenblatt A, et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet 2001; 29:377-378. (Pubitemid 34326684)
12. Margolis RL, Holmes SE, Rosenblatt A, et al. Huntington's disease-like 2 (HDL2) in North America and Japan. Ann Neurol 2004; 56:670-674. (Pubitemid 39540747)
13. Margolis RL, Rudnicki DD, Holmes SE. Huntington's disease like-2: review and update. Acta Neurol Taiwan 2005; 14:1-8. (Pubitemid 40515830)
14. Schneider SA, Marshall KE, Xiao J, LeDoux MS. JPH3 repeat expansions cause a progressive akinetic-rigid syndrome with severe dementia and putaminal rim in a five-generation African-American family. Neurogenetics 2012; 13:133-140.
15. Stevanin G, Camuzat A, Holmes SE, et al. CAG/CTG repeat expansions at the Huntington's disease-like 2 locus are rare in Huntington's disease patients. Neurology 2002; 58:965-967. (Pubitemid 34242078)
16. Stevanin G, Fujigasaki H, Lebre AS, et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 2003; 126:1599-1603. (Pubitemid 36834936)
17. Wild EJ, Mudanohwo EE, Sweeney MG, et al. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008; 23:716-720.
18. Krause A, Greenberg J. Genetic testing for Huntington's disease in South Africa. S Afr Med J 2008; 98:193-194. (Pubitemid 351516343)
19. Magazi DS, Krause A, Bonev V, et al. Huntington's disease: genetic heterogeneity in black African patients. S Afr Med J 2008; 98:200-203. (Pubitemid 351516346)
20. Santos C, Wanderley H, Vedolin L, et al. Huntington disease-like 2: the first patient with apparent European ancestry. Clin Genet 2008; 73:480-485. (Pubitemid 351517263)
21. Greenstein PE, Vonsattel JP, Margolis RL, Joseph JT. Huntington's disease like-2 neuropathology. Mov Disord 2007; 22:1416-1423. (Pubitemid 47280626)
22. Margolis RL, O'Hearn E, Rosenblatt A, et al. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann Neurol 2001; 50:373-380. (Pubitemid 32848740)
23. Rudnicki DD, Pletnikova O, Vonsattel JP, et al. A comparison of Huntington disease and Huntington disease-like 2 neuropathology. J Neuropathol Exp Neurol 2008; 67:366-374. (Pubitemid 351507491)
24. Seixas AI, Holmes SE, Takeshima H, et al. Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis. Ann Neurol 2012; 71:245-257.
25. Rudnicki DD, Holmes SE, Lin MW, et al. Huntington's disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007; 61:272-282. (Pubitemid 46557351)
26. Kambouris M, Bohlega S, Al-Tahan A, Meyer BF. Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am J Hum Genet 2000; 66:445-452. (Pubitemid 30468822)
27. Nakamura K, Jeong SY, Uchihara T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001; 10:1441-1448. (Pubitemid 32684885)
28. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 2000; 23:387-392.
29. Toyoshima Y, Onodera O, Yamada M, et al. Spinocerebellar ataxia type 17. Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. Seattle (WA): University of Washington; 1993.
30. Gao R, Matsuura T, Coolbaugh M, et al. Instability of expanded CAG/CAA repeats in spinocerebellar ataxia type 17. Eur J Hum Genet 2008; 16:215-222.
31. Rasmussen A, De Biase I, Fragoso-Benitez M, et al. Anticipation and intergenerational repeat instability in spinocerebellar ataxia type 17. Ann Neurol 2007; 61:607-610. (Pubitemid 47068144)
32. Stevanin G, Brice A. Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum 2008; 7:170-178.
33. Craig K, Keers SM, Walls TJ, et al. Minimum prevalence of spinocerebellar ataxia 17 in the north east of England. J Neurol Sci 2005; 239:105-109. (Pubitemid 41617422)
34. Schneider SA, Walker RH, Bhatia KP. The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test. Nat Clin Pract Neurol 2007; 3:517-525. (Pubitemid 47377611)
35. Rolfs A, Koeppen AH, Bauer I, et al. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol 2003; 54:367-375. (Pubitemid 37072039)
36. Loy CT, Sweeney MG, Davis MB, et al. Spinocerebellar ataxia type 17: extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging. Mov Disord 2005; 20:1521-1523. (Pubitemid 43072664)
37. Brockmann K, Reimold M, Globas C, et al. PET and MRI reveal early evidence of neurodegeneration in spinocerebellar ataxia type 17. J Nucl Med 2012; 53:1074-1080.
38. Schols L, Bauer P, Schmidt T, et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004; 3:291-304. (Pubitemid 38510200)
39. Naito H, Oyanagi S. Familial myoclonus epilepsy and choreoathetosis: hereditary dentatorubral-pallidoluysian atrophy. Neurology 1982; 32:798-807. (Pubitemid 12097663)
40. Nagafuchi S, Yanagisawa H, Sato K, et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet 1994; 6:14-18. (Pubitemid 24191906)
41. Koide R, Ikeuchi T, Onodera O, et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994; 6:9-13.
42. Nagafuchi S, Yanagisawa H, Ohsaki E, et al. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nat Genet 1994; 8:177-182. (Pubitemid 24308366)
43. Tsuji S. Dentatorubral-pallidoluysian atrophy. Handb Clin Neurol 2012; 103:587-594.
44. Tsuji S. Dentatorubral-pallidoluysian atrophy (DRPLA): clinical features and molecular genetics. Adv Neurol 1999; 79:399-409.
45. Sunami Y, Koide R, Arai N, et al. Radiologic and neuropathologic findings in patients in a family with dentatorubral-pallidoluysian atrophy. AJNR Am J Neuroradiol 2011; 32:109-114.
46. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28:350-354. (Pubitemid 32702424)
47. Vidal R, Ghetti B, Takao M, et al. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol 2004; 63:363-380. (Pubitemid 38429033)
48. Ohta E, Nagasaka T, Shindo K, et al. Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene. Neurology 2008; 70:1493-1494. (Pubitemid 351521946)
49. Mancuso M, Davidzon G, Kurlan RM, et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol 2005; 64:280-294. (Pubitemid 40489555)
50. Maciel P, Cruz VT, Constante M, et al. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 2005; 65:603-605. (Pubitemid 41170724)
51. Kubota A, Hida A, Ichikawa Y, et al. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov Disord 2009; 24: 441-445.
52. Devos D, Tchofo PJ, Vuillaume I, et al. Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain 2009; 132: e109.
53. Chinnery PF. Neuroferritinopathy. Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. Seattle (WA): University of Washington; 1993.
54. Ohta E, Takiyama Y. MRI findings in neuroferritinopathy. Neurol Res Int 2012; 2012:197438.
55. Shah SO, Mehta H, Fekete R. Late-onset neurodegeneration with brain iron accumulation with diffusion tensor magnetic resonance imaging. Case Rep Neurol 2012; 4:216-223.
56. Devriendt K, Vanhole C, Matthijs G, de Zegher F. Deletion of thyroid transcription factor-1 gene in an infant with neonatal thyroid dysfunction and respiratory failure. N Engl J Med 1998; 338:1317-1318. (Pubitemid 28216593)
57. Kimura S. Thyroid-specific enhancer-binding protein role in thyroid function and organogenesis. Trends Endocrinol Metab 1996; 7:247-252. (Pubitemid 26325878)
58. Gras D, Jonard L, Roze E, et al. Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene. J Neurol Neurosurg Psychiatry 2012; 83:956-962.
59. Mahajnah M, Inbar D, Steinmetz A, et al. Benign hereditary chorea: clinical, neuroimaging, and genetic findings. J Child Neurol 2007; 22: 1231-1234.
60. Kleiner-Fisman G, Rogaeva E, Halliday W, et al. Benign hereditary chorea: clinical, genetic, and pathological findings. Ann Neurol 2003; 54:244-247. (Pubitemid 36909624)
61. Kleiner-Fisman G, Calingasan NY, Putt M, et al. Alterations of striatal neurons in benign hereditary chorea. Mov Disord 2005; 20:1353-1357. (Pubitemid 41645913)
62. Wheeler PG, Weaver DD, Dobyns WB. Benign hereditary chorea. Pediatr Neurol 1993; 9:337-340. (Pubitemid 23325149)
63. Asmus F, Horber V, Pohlenz J, et al. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa. Neurology 2005; 64:1952-1954. (Pubitemid 40800715)
64. Shimohata T, Hara K, Sanpei K, et al. Novel locus for benign hereditary chorea with adult onset maps to chromosome 8q21.3 q23.3. Brain 2007; 130:2302-2309. (Pubitemid 47327620)
65. Walker RH, Jung HH, Dobson-Stone C, et al. Neurologic phenotypes associated with acanthocytosis. Neurology 2007; 68:92-98. (Pubitemid 46071891)
66. Rampoldi L, Dobson-Stone C, Rubio JP, et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 2001; 28:119-120. (Pubitemid 32538051)
67. Ueno S, Maruki Y, Nakamura M, et al. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet 2001; 28:121-122. (Pubitemid 32538052)
68. Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. Orphanet J Rare Dis 2011; 6:68.
69. Bader B, Walker RH, Vogel M, et al. Tongue protrusion and feeding dystonia: a hallmark of chorea-acanthocytosis. Mov Disord 2010; 25:127-129.
70. Schneider SA, Lang AE, Moro E, et al. Characteristic head drops and axial extension in advanced chorea-acanthocytosis. Mov Disord 2010; 25:1487-1491.
71. Danek A, Walker RH. Neuroacanthocytosis. Curr Opin Neurol 2005; 18:386-392. (Pubitemid 41104800)
72. Storch A, Kornhass M, Schwarz J. Testing for acanthocytosis. A prospective reader-blinded study in movement disorder patients. J Neurol 2005; 252:84-90. (Pubitemid 40179023)
73. Henkel K, Danek A, Grafman J, et al. Head of the caudate nucleus is most vulnerable in chorea-acanthocytosis: a voxel-based morphometry study. Mov Disord 2006; 21:1728-1731. (Pubitemid 44742206)
74. Walterfang M, Yucel M, Walker R, et al. Adolescent obsessive compulsive disorder heralding chorea-acanthocytosis. Mov Disord 2008; 23:422-425.
75. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991; 114:13-49.
76. Rinne JO, Daniel SE, Scaravilli F, et al. The neuropathological features of neuroacanthocytosis. Mov Disord 1994; 9:297-304. (Pubitemid 24150113)
77. Danek A, Rubio JP, Rampoldi L, et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001; 50:755-764. (Pubitemid 33116135)
78. Danek A, Tison F, Rubio J, et al. The chorea of McLeod syndrome. Mov Disord 2001; 16:882-889. (Pubitemid 36041190)
79. Gantenbein AR, Damon-Perriere N, Bohlender JE, et al. Feeding dystonia in McLeod syndrome. Mov Disord 2011; 26:2123-2126.
80. Jung HH, Danek A, Frey BM. McLeod syndrome: a neurohaematological disorder. Vox Sang 2007; 93:112-121. (Pubitemid 47228502)
81. Oechslin E, Kaup D, Jenni R, Jung HH. Cardiac abnormalities in McLeod syndrome. Int J Cardiol 2009; 132:130-132.
82. Taly AB, Meenakshi-Sundaram S, Sinha S, et al. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007; 86:112-121. (Pubitemid 46668060)
83. Schneider SA, Klein C. What is the role of genetic testing in movement disorders practice? Curr Neurol Neurosci Rep 2011; 11:351-361.